TNNT2 and cancer: This was the case for cancer patients (hs-cTnT > 14 ng/L: 64.6%, p < 0.0001, log-rank test; NT-proBNP > 300 ng/L: 62.9%, p < 0.0001, log-rank test) and non-cancer patients (hs-cTnT > 14 ng/L: 50.0%, p < 0.0001, log-rank test; NT-proBNP > 300 ng/L: 44.2%, p < 0.0001, log-rank test).